title: Reversible Fanconi syndrome in a pediatric patient on deferasirox.
abstract: Deferasirox (Exjade®, Novartis) is a widely used oral iron chelator for the treatment of patients with iron overload due to chronic transfusion therapy for diseases such as β-thalassemia and sickle cell disease. Renal side effects of deferasirox are common and include non-progressive increases in serum creatinine, however, the effect of deferasirox on proximal tubule function is unclear. We report one pediatric patient with reversible Fanconi syndrome associated with long-term deferasirox therapy and one patient with mild proximal tubular dysfunction. Kidney and proximal tubular function should be periodically monitored in patients receiving deferasirox throughout their course of therapy.
authors.affiliation: Department of Pediatrics, University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota 55455, USA. rheau002@umn.edu
authors.forename: Michelle N
authors.initials: MN
authors.lastname: Rheault
authors.forename: Heather
authors.initials: H
authors.lastname: Bechtel
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Neglia
authors.forename: Clifford E
authors.initials: CE
authors.lastname: Kashtan
mesh_terms: D001565:Benzoates / Q000009:adverse effects*; D002648:Child; D000077588:Deferasirox; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D005198:Fanconi Syndrome / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology; D008297:Male; D014230:Triazoles / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000628:therapy
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox